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Abstract
The purpose of this study was to examine the correlation between high-resolution magic angle spinning (HR-MAS)
magnetic resonance (MR) spectroscopy using core needle biopsy (CNB) specimens and histologic prognostic factors
currently used in breast cancer patients. After institutional review board approval and informed consent were obtained for
this study, CNB specimens were collected from 36 malignant lesions in 34 patients. Concentrations and metabolic ratios of
various choline metabolites were estimated by HR-MAS MR spectroscopy using CNB specimens. HR-MAS spectroscopic
values were compared according to histopathologic variables [tumor size, lymph node metastasis, histologic grade, status
of estrogens receptor (ER), progesterone receptor (PR), HER2 (a receptor for human epidermal growth factor), and Ki-67, and
triple negativity]. Multivariate analysis was performed with Orthogonal Projections to Latent Structure-Discriminant Analysis
(OPLS-DA). HR-MAS MR spectroscopy quantified and discriminated choline metabolites in all CNB specimens of the 36
breast cancers. Several metabolite markers [free choline (Cho), phosphocholine (PC), creatine (Cr), taurine, myo-inositol,
scyllo-inositol, total choline (tCho), glycine, Cho/Cr, tCho/Cr, PC/Cr] on HR-MAS MR spectroscopy were found to correlate
with histologic prognostic factors [ER, PR, HER2, histologic grade, triple negativity, Ki-67, poor prognosis]. OPLS-DA
multivariate models were generally able to discriminate the status of histologic prognostic factors (ER, PR, HER2, Ki-67) and
prognosis groups. Our study suggests that HR-MAS MR spectroscopy using CNB specimens can predict tumor
aggressiveness prior to surgery in breast cancer patients. In addition, it may be helpful in the detection of reliable
markers for breast cancer characterization.
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Introduction
Breast cancer is one of the most common cancers and is an
important cause of cancer related deaths among women globally
[1,2]. Early diagnosis of breast cancer is crucial for successful
treatment and screening programs using mammography, ultraso-
nography, and magnetic resonance imaging (MRI) have been
effective in industrialized countries [3–6]. In addition to early
detection, clinical and histologic assessments of breast cancer are
also important components in treatment and management. The
presence of hormone receptors is a generally favorable sign of
prognosis, as appropriate hormone therapy can suppress the
growth of such tumors. Patients with large tumors and axillary
lymph node metastasis are considered to be at high risk of tumor
recurrence, and these patients require more extensive treatment.
Therefore, the identification of reliable markers to improve
diagnostic accuracy and predict prognosis would be an important
accomplishment.
High-resolution magic angle spinning (HR-MAS) magnetic
resonance (MR) spectroscopy has been applied in studies of
various human tissues and diseases [7–10]. The HR-MAS MR
spectra of tissue samples consist of multiple peaks that provide
information on their metabolic composition. The assessment of
tumor metabolic composition with HR-MAS MR spectroscopy
has been suggested as a promising tool in the diagnosis and
characterization of breast cancer [11–13]. Recent studies using
HR-MAS MR spectroscopy have also reported that the choline-
containing compounds of breast cancer tissue, including glycer-
ophosphocholine (GPC), phosphocholine (PC), free choline (Cho),
and taurine (Tau), have different concentrations and distributions
according to clinicopathologic parameters associated with tumor
aggressiveness [14–16]. However, these studies performed HR-
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MAS MR spectroscopy using surgically obtained tissue specimens.
Therefore, their results could not be directly applied to the
preoperative decision making stage at which treatment approaches
are planned for patients with breast cancer.
Percutaneous image-guided core needle biopsy (CNB) is a
minimally invasive and widely used procedure for the diagnosis of
breast cancer prior to surgery [17]. Tissue samples obtained with
CNB are clinically useful not only for pathologic diagnosis but also
for immunohistochemical (IHC) analysis of histologic prognostic
factors such as hormone receptor status [18]. Recently, Li et al.
performed HR-MAS MR spectroscopy on breast tissue samples
obtained with CNB, and showed that this approach has the
potential to discriminate between cancer and non-cancer samples
[19].
Therefore, we hypothesized that HR-MAS MR spectroscopy
performed on breast cancer tissues obtained via CNB may
correlate with histologic prognostic factors and that it may help
identify reliable markers for the characterization of breast cancer.
The purpose of this study was to determine whether there are any
correlations between HR-MAS MR spectroscopy data for CNB
specimens and histologic prognostic factors currently used in
breast cancer patients.
Materials and Methods
Patients
This study was approved by the institutional review board of
Yonsei University College of Medicine, and written informed
consent was obtained from each patient prior to study com-
mencement. Between August 2010 and February 2011, 38 female
patients (mean age 52.2 years; age range 34–68 years) with a total
of 40 breast lesions as assessed by the Breast Imaging Reporting
and Data System (BI-RADS) staged 4c or 5 and larger than 1 cm
in diameter on mammographic or US imaging were initially
enrolled. All patients underwent ultrasound (US)-guided CNB for
diagnosis. Of these, 34 patients with 36 breast lesions fulfilled the
following inclusion criteria: 20 years of age or older; having a
breast lesion pathologically diagnosed as malignant by core biopsy;
not pregnant at the time of diagnosis; no history of breast cancer
or previous breast surgery including breast implants. We
performed HR-MAS MR spectroscopy on the CNB specimens
from the 36 malignant breast lesions.
1H NMR Spectroscopy using Biopsy Specimens
The US-guided CNBs were performed with a 14-gauge dual-
action semiautomatic core biopsy needle (Stericut with coaxial
guide; TSK Laboratory, Tochigi, Japan) by one of four
radiologists (with 6–13 years of experience). In large cancers with
a heterogeneous nature, the homogeneously solid areas were
targeted for biopsies. The mean number of tissue samples obtained
by US-guided CNB was six (range 5–8) core samples. For HR-
MAS MR spectroscopy, one core tissue sample was put in a
cryogenic vial and immersed in liquid nitrogen immediately after
biopsy. Samples were stored at -162uC for one to five months prior
to HR-MAS MR spectroscopy.
HR-MAS MR spectroscopy was performed on the tissue
samples with an NMR (nuclear magnetic resonance) spectrometer
(Agilent, VNMRS 500) operating at a proton NMR frequency of
500.13 MHz (11.74T). The temperature was set to 19uC after
calibration with methanol. The examination time of each sample
was approximately 1 hour. Frozen samples were thawed in the
NMR laboratory, weighed, and placed in a HR-MAS nano-
probeH (Agilent, Walnut Creek, CA, USA). The total volume of
the sample cell was 40 ml, and an average of 7.5 mg core-biopsy
samples were put in the cell with the remaining volume filled with
D2O containing 0.01% trimethylsilyl propionic acid (TSP). An
inverse-detection type probe was equipped with a single Z-
gradient coil was used. The spectra were acquired with a CPMG
pulse sequence to impose a T2 filter. The total T2 delay was set to
290 msec and the samples were spun at 2 KHz. The spectra were
acquired with total complex points of 16 K, sweep width of
7961 Hz, and 1024 transients. The 90 degree pulse was calibrated
with each sample on water resonance. The water signal was
saturated using a continuous weak power wave during the recycle
delay. Each free induction decay signal was processed and
analyzed using ACD software (Advanced Chemistry Develop-
ment, Toronto, Ontario, Canada). Post-processing consisted of
Fourier transformation, phasing and baseline correction. Chemical
shifts were referenced in relation to the creatine (Cr) signal at
3.04 ppm. Spectral regions from 1.47 to 3.60 ppm [alanine (Ala),
succinate (Suc), Cr, Cho, PC, GPC, myo-inositol (m-Ins), scyllo-
inositol (s-Ins), Tau, glycine (Gly)] were selected for quantification
(Fig. 1). Metabolite peak amplitudes were measured by fitting a
Voigt (e.g., Gauss+Lorentz) lineshape function. The integration
values were normalized to the number of contributing protons per
molecule and to tissue weight. Quantification was performed by
comparing the integrated TSP signal with the signal of interest in
the tumor spectrum. Absolute concentrations were recorded as
means6SD in mmol/g wet weight.
Histopathologic Analysis
All 36 lesions were pathologically diagnosed as malignant by
CNB prior to treatment. The final diagnosis was established with
surgery in 29 patients with 31 malignant lesions (one patient had
bilateral breast cancers and one patient had multicentric breast
cancers found in two quadrants of the breast). In the remaining
five patients with five malignant lesions, the final diagnosis was
confirmed by CNB without surgery. The final histopathologic
results were used as reference standards. Information about
pathologic variables including histologic grade, estrogen receptor
(ER), progesterone receptor (PR), HER2 (a receptor for human
epidermal growth factor), and Ki-67 status was based on final
pathologic reports.
All tissues were fixed in 10% buffered formalin and embedded
in paraffin. All archival hematoxylin and eosin (H&E)-stained
slides for each case were reviewed by experienced pathologists.
The histologic grade of each tumor was determined with the
modified Bloom-Richardson classification [20].
IHC analyses for ER, PR, HER2, and Ki-67 were performed
on tissue blocks. Briefly, 5 mm-thick sections were obtained with a
microtome, deparaffinized and rehydrated. After a 10 minute
treatment with 3% hydrogen peroxide solution to block endog-
enous peroxidases, the sections were pretreated in 10 mM citrate
buffer (pH 6.0) for antigen retrieval in a microwave oven for 20
minutes. After incubation with primary antibodies against ER
(clone SP1, 1:100; Thermo Scientific, Fremont, CA, USA), PR
(clone PgR 636, 1:50; DAKO, Glostrup, Denmark), HER2
(polyclonal, 1:1500; DAKO), and Ki-67 (1:400 dilution; Novocas-
tra, Newcastle, U.K.), immunodetection was performed with
biotinylated antimouse immunoglobulin, followed by peroxidase-
labeled streptavidin using a labeled streptavidin biotin kit with
3,39-diaminobenzidine chromogen as the substrate. Slides were
counterstained with Harris hematoxylin. ER and PR positivity was
defined as more than 10 fmol/mg cytosol protein, or as 10% or
more nuclear IHC staining. IHC stain results of HER2 were
scored by counting the number of cells positively stained on the
membrane and expressed as a percentage of total tumor cells.
HER2 staining was scored as follows: 0, membrane staining in
HR-MAS MR Spectroscopy of Breast Cancer Tissue
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,10% of tumor cells; 1+, faint or incomplete membrane staining
in .10% of cells; 2+, weak or moderate complete or incomplete
staining in .10% of cells; 3+, strong complete membrane staining
in .10% of cells. Tumors scored as 3+ were considered HER2
positive cases whereas tumors with 0 to 1+ were regarded as
negative cases. Borderline cases (2+) required further investigation
using fluorescence in situ hybridization to assess gene amplification.
Triple negativity was defined as the complete lack of expression of
ER, PR, and HER2. IHC staining of Ki-67 was scored by
counting the number of cells with positively stained nuclei and
expressed as a percentage of the total tumor cells. Staining results
for Ki-67 were classified as follows: Group 1: #10%, Group 2:10–
29%, and Group 3: $30% [21].
Data and Statistical Analysis
Patients’ clinicopathologic data was collected from a review of
their medical records. Clinicopathologic variables included the
pathologic type of each tumor, lymph node metastasis at the time
of diagnosis, tumor size, histologic grade, status of ER, PR, HER2
and Ki-67 expression, and triple negativity (Table 1). Tumor size
was based on final pathologic results (n = 22). However, tumor size
measured with US was used when patients received neoadjuvant
chemotherapy before surgery (n = 9) or did not undergo surgery
(n = 5).
HR-MAS MR spectroscopic values (Metabolite Concentrations:
Cho, PC, GPC, total choline (tCho, the sum of Cho, PC, and
GPC), Cr, Gly, Tau, m-Ins, s-Ins/Metabolic Ratios: Cho/Cr, PC/
Cr, GPC/Cr, GPC/PC, GPC/Cho, PC/Cho) were compared
according to histopathologic prognostic factors using the Student’s
t-test. Tumors were grouped by size based on diameter #2 cm or
.2 cm. In addition, tumors were grouped by prognosis. The good
prognosis group was defined by no spread to axillary lymph nodes,
a tumor size with a diameter #2 cm, and positive results for ER
and PR. The poor prognosis group was defined by detection of
axillary lymph node metastasis, a tumor size with a diameter
.2 cm, or negative results for ER or PR. Statistical analysis was
done with SAS for Windows, version 9.0 (SAS Institute, Cary, NC,
USA). Statistical significance was defined as a P- value ,0.05.
For multivariate analysis of spectral data, Matlab (MathWorks,
Natick, MA), SIMCA-P 11.0 (Umetrics,Sweden), and Excel
(Microsoft, Seattle, WA) programs were used to process the
numeric data. Principal component analysis, partial least square-
discriminant analysis, and Orthogonal Projections to Latent
Structure-Discriminant Analysis (OPLS-DA) were performed to
distinguish patient groups by prognostic factors shown to have
significant association with HR-MAS spectroscopic values in
univariate analysis. Class discrimination models were built until
the cross-validated predictability value did not meaningfully
increase to avoid over-fitting of the statistical model. The statistical
model was validated by prediction of unknown samples using a
leave-one out analysis. An a priori cut-off value of 0.5 was used to
evaluate the prediction results [22]. Signals contributing to class
differentiation were identified by the S-plot and the corresponding
metabolites were identified using Chenomx (Spectral database;
Edmonton, Alberta, Canada) software and an in-house built
database.
Results
The mean tumor size was 29.7 mm (range, 10–80 mm). The
most common tumor type was invasive ductal carcinoma (n= 30),
Figure 1. A 38-year-old woman with invasive ductal carcinoma (tumor size 37 mm, triple negative, strongly positive Ki-67). The HR-
MAS MR spectrum (11.7T) obtained using the core needle biopsy specimen shows peaks of each choline metabolite. The tCho concentration
measured with HR-MAS MR spectroscopy was 6.5 mmol/kg. Note. Lac, lactate; Ala, alanine; Glu, glutamate; Cr, creatine; Cho, free choline; GPC,
glycerophosphocholine; PC, phosphocholine; tCho, total choline, sum of Cho, PC, and GPC; Tau, taurine; m-Ins, myo-inositol; Gly, glycine.
doi:10.1371/journal.pone.0051712.g001
HR-MAS MR Spectroscopy of Breast Cancer Tissue
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and other cancers were 3 DCIS, 1 mucinous carcinoma, 1 tubular
carcinoma, and 1 invasive micropapillary carcinoma.
HR-MAS MR spectroscopy quantified and discriminated
various choline metabolites in all 36 breast cancer tissues obtained
with CNB (Table 2, Fig. 1). The mean and median values of tCho
concentration were 1.95 mmol/g (range, 0.06–6.55) and
1.46 mmol/g (interquartile range 0.61–3.0), respectively. The
mean and median values of PC concentration were higher than
those of Cho or GPC.
As shown in Table 3, we found that several metabolite markers
identified on HR-MAS MR spectroscopy that correlated with
histopathologic prognostic markers. ER negative cancers showed
higher Cho concentrations than ER positive cancers (p = 0.03). PR
negative cancers showed higher concentrations of Cho, Cr, and
Tau than those of PR positive cancers (p = 0.01, p = 0.02, and
p= 0.02, respectively). Between HER2 positive and negative
groups, concentrations of Tau, s-Ins, and m-Ins of HER2 positive
cancers were significantly higher than those of the HER2 negative
cancers (p = 0.01, p = 0.03, and p=0.01, respectively). Cancers
with high histologic grade showed higher PC/Cr than those of
cancers with low histologic grade (p = 0.04). Triple negative
cancers showed higher Cho concentrations and higher values of
Cho/Cr and tCho/Cr than those of non-triple negative cancers.
Cancers strongly positive for Ki-67 showed higher concentrations
of tCho and PC, and higher values of PC/Cr than those of cancers
weakly positive for Ki-67 (p= 0.01). The poor prognosis group
showed higher Gly and s-Ins concentrations than those of the good
prognosis group (p = 0.02 and p= 0.01, respectively). The
histologic grade, tumor size, and lymph node metastasis did not
correlate with HR-MAS MR spectroscopic values.
OPLS-DA separation models were produced with the HR-MAS
MR spectral data by prognostic factors shown to have significant
association in univariate analysis (ER, PR, HER2, Ki-67 status
and prognosis). OPLS-DA score plots showed visible discrimina-
tion by status of ER, PR, HER2, and Ki-67 (Fig. 2), although some
samples crossed over the reference line. In addition, reasonable
distinction was observed between the good and poor prognosis
groups. Triple negativity status could not be evaluated due to the
small number of triple negative cancer samples in our study (n= 4).
Discussion
In breast cancer research, most previous studies employing HR-
MAS MR spectroscopy have used surgically obtained tissue
specimens [8,15,16]. Therefore, their results have not been able to
strongly influence the diagnosis of breast tumors or the preoper-
ative decision making stage at which cancer treatment is planned.
In this study, we conducted HR-MAS MR spectroscopy using 14-
gauge CNB specimens. The tCho concentration (range, 0.06–
6.55 mmol/g) acquired in our study with 11.7-T HR-MAS MR
spectroscopy using CNB specimens was consistent with values
reported in previous studies that used surgical specimens for HR-
MAS MR spectroscopy [16]. US-guided CNB is the most
frequently used procedure for diagnosis of suspicious breast
lesions, therefore HR-MAS MR spectroscopic values for US-
guided CNB specimens can be clinically applicable for diagnosis or
characterization of breast cancers to decide treatment options such
as neoadjuvant chemotherapy. In addition, CNB samples can be
re-used for later histopathologic examinations after HR-MAS MR
spectroscopy, because HR-MAS MR spectroscopy does little
damage to the integrity of the tissue samples during examination
[14,19].
Choline-containing compounds are associated with cell signal-
ing, lipid metabolism and cell membrane integrity [23,24]. Many
Table 1. Clinicopathologic data of 34 patients with 36
malignant breast lesions in this study.
Clinicopathologic variables Patients (%) Lesions (%)
Histologic grade Low (Grade 1–2 ) 24 (70.6) 26 (72.3)
High (Grade 3) 10 (39.4) 10 (27.7)
Tumor size #2 cm 15 (44.1) 17 (47.2)
.2 cm 19 (55.9) 19 (52.8)
ER status Negative 6 (17.7) 6 (16.6)
Positive 26 (76.4) 28 (77.8)
N/A 2 (5.9) 2 (5.6)
PR status Negative 18 (52.9) 18 (50.0)
Positive 14 (41.2) 16 (44.4)
N/A 2 (5.9) 2 (5.6)
HER2 status Negative 27 (79.4) 29 (80.5)
Positive 5 (14.7) 5 (13.9)
N/A 2 (5.9) 2 (5.6)
Triple negativity Yes 4 (11.7) 4 (11.1)
No 28 (82.4) 30 (83.3)
N/A 2 (5.9) 2 (5.6)
Ki-67 status Low (Group 1–2) 24 (70.6) 26 (72.3)
High (Group 3) 6 (17.7) 6 (16.6)
N/A 4 (11.7) 4 (11.1)
Lymph node
metastasis
Negative 22 (64.7) 24 (66.7)
Positive 12 (35.3) 12 (33.3)
Prognosis Good 7 (20.6) 9 (25.0)
Poor 25 (73.5) 25 (69.4)
N/A: not available.
doi:10.1371/journal.pone.0051712.t001
Table 2. HR-MAS MR spectroscopy values for 36 breast
cancer specimens.
Metabolite concentration
(mmol/g) Metabolic ratio
Metabolite Mean±SD (Median) Ratio Mean±SD (Median)
Cho 0.3660.28 (0.29) Cho/Cr 1.7660.99 (1.53)
PC 1.3461.26 (0.88) PC/Cr 1.7761.20 (1.57)
GPC 0.2560.24 (0.19) GPC/Cr 1.0660.75 (0.83)
tCho 1.9561.63 (1.46) tCho/Cr 4.6062.17 (3.86)
Cr 0.6660.47 (0.61) GPC/PC 0.7360.61 (0.60)
Gly 0.9661.17 (0.62) GPC/Cho 0.7260.63 (0.55)
Tau 1.8361.41 (1.56) PC/Cho 1.2861.08 (1.20)
s-Ins 0.5660.58 (0.44)
m-Ins 0.8660.88 (0.53)
Ala 0.7960.69 (0.62)
Suc 0.1560.13 (0.09)
Data represent the mean 6 standard deviation (median).
Cho: choline, PC: phosphocholine, GPC: glycerophosphocholine, tCho: total
choline (the sum of Cho, PC, and GPC), Cr: creatine, Tau: taurine, Gly: glycine, m-
Ins: myo-inositol, s-Ins: scyllo-inositol, Ala: alanine, Suc: succinate.
doi:10.1371/journal.pone.0051712.t002
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studies have reported that choline-containing compounds, espe-
cially PC, are elevated in breast cancer tissue compared to its
normal counterparts [11,15,16,25–28]. The higher concentrations
of choline-containing compounds in breast cancer tissue may be a
consequence of overexpression and changes in the levels of choline
kinase activity in response to demands from the cell for increased
phospholipid synthesis [29,30]. In this study, HR-MAS MR
spectroscopy quantified choline-containing compounds in all 36
cancer CNB samples of our patient group. HR-MAS MR spectra
discriminated and quantified PC, GPC, and Cho, which
contribute to the tCho peak signal. Concentrations of PC, GPC,
and Cho were consistent with previously reported values, and PC
was the main contributor of the Cho peak signal [15,16]. A
previous study by Li et al. showed that HR-MA MR spectroscopy
on breast tissues obtained with CNB could clearly discriminate
between cancer and non-cancer samples using metabolomics,
although the data did not show the absolute concentrations for
each Cho metabolite in the tissue samples [19]. Considering this
Figure 2. Orthogonal Projections to Latent Structure-Discriminant Analysis (OPLS-DA) score plot for estrogen receptor (ER),
progesterone receptor (PR), HER2, Ki-67 status, and prognosis.
doi:10.1371/journal.pone.0051712.g002
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with our own results, it is possible to infer that HR-MAS MR
spectroscopy using CNB specimens may have a potential role in
the diagnosis of breast cancer, although we did not evaluate non-
cancer samples.
Some HR-MAS MR spectroscopic values (Cho, PC, Tau, s-Ins,
m-Ins, Gly, Cho/Cr, tCho/Cr, PC/Cr) were found to be
significantly correlated with known histopathologic prognostic
factors (ER, PR, HER2, and Ki-67 status, histologic grade, triple
negativity) and the poor prognosis group. In this study, concen-
trations and metabolic ratios of choline-containing compounds
were elevated in ER-negative, PR-negative, HER2-positive, high
histologic grade, strongly Ki-67 positive, and triple negative breast
cancers. In addition, concentrations of Gly and s-Ins were
significantly higher in the poor prognosis group than those of
the good prognosis group. Our study showed that ER, PR, HER2,
Ki-67 status, and the prognosis group correlated with HR-MAS
MR spectroscopic values on CNB cancer samples through a
OPLS-DA multivariate analysis. These results suggest that the
aggressiveness and proliferative activity of breast cancer correlate
with HR-MAS MR spectroscopic values for tissue samples
obtained using CNB. Li et al. also showed relevant correlation
of HR-MAS MR spectral data of CNB cancer samples with PR
and lymph node metastasis status [19], although our study could
not confirm the latter as lymph node metastasis did not show
significant association with spectroscopic values in our univariate
analysis. However, they were not able to evaluate ER and HER2
status due to the small number of patients in their cancer patient
group. Looking at the results of other previous studies with our
own results together, we can therefore expect HR-MAS MR
spectroscopic values to be used as reliable markers for prognosis
prediction in breast cancer patients. In order to confirm the
relationship between HR-MAS MR spectroscopic values and
prognosis, future studies about whether or not HR-MAS MR
spectroscopic values are independent factors for breast cancer
prognosis will be needed for large numbers of cancers.
Principal component analysis (PCA) and partial least square-
discriminate analysis (PLS-DA) have been used in breast cancer
metabolomics [14,31]. OPLS-DA, which was used for our
multivariate analysis, is an extension of the PLS-DA featuring an
integrated orthogonal signal correction. The main benefit of
OPLS-DA lies in the ability to separate the class-orthogonal
variations that can obscure class discrimination. To date, the
OPLS-DA has shown its utility in classifying data that has large
intra-group variations such as the MR spectroscopic data of our
study [32,33]. In our study, OPLS-DA models provided visible
discrimination of HR-MAS MR spectral data by prognostic
factors.
Among the HR-MAS MR spectroscopic values significantly
correlated with histologic prognostic factors in this study, PC and
Cho are already well-known markers for breast cancer
[15,16,26,34,35]. On the other hand, recent reports state that
elevated levels of Tau and Gly can also be associated with breast
cancer tissue [15,16,36]. Tau is an amino acid involved in many
essential biological functions such as antioxidation, membrane
stabilization, and cell shrinkage during apoptosis [37–40]. Cao
et al. reported that the treatment response of breast cancer
patients receiving neoadjuvant chemotherapy was best predicted
by Tau among various choline metabolites obtained with HR-
MAS MR spectroscopy [36]. In this study, non-survivor had lower
Tau concentration and significantly lower Tau/Gly ratio com-
pared to survivors at pre- and post-treatment. Meanwhile, Gly is
an amino acid known as a precursor to proteins and the role of Gly
in the development or progression of cancer is currently unknown.
However, Gly has been found to contribute to characterization of
breast cancer tissue in previous reports [16,36,41]. Sitter el al.
reported that Gly concentrations were significantly higher in
breast cancers larger than 2 cm compared to those of smaller
cancers [16]. Cao et al. showed survivors had a significant
decrease in Gly concentration after neoadjuvant chemotherapy,
while it remained unchanged in non-survivors [36]. Jain et al.
recently identified the correlation of Gly consumption and
synthesis with rapid cancer cell proliferation, and a higher
expression of the mitochondiral Gly biosynthesis pathway is
associated with higher mortality in breast cancer patients [41].
Although the precise mechanisms of these findings are not known,
our study also showed higher concentrations of Tau and Gly being
associated with PR negative/HER2 positive cancers and the poor
prognosis group, respectively. Accordingly, we suggest that Tau
and Gly may be reliable markers in predicting treatment response
or in suggesting poor prognosis during therapeutic monitoring of
breast cancer patients. Besides these markers, Ala, Suc, and several
polyunsaturated fatty acids were reported as biomarkers related to
metabolism in cancer [34,42,43]. We could quantify these
metabolites using HR-MAS MR data of our breast cancer tissues,
although these values did not show significant correlation with
prognostic factors. Therefore, further studies to assess the most
reliable marker among the various HR-MAS MR spectroscopic
values will be needed for breast cancer research.
In vivo proton MR spectroscopy has been studied extensively as
an adjunctive technique for breast cancer imaging. This is a
method that can provide metabolic information about tumors
noninvasively, while HR-MAS MR spectroscopy requires an
invasive procedure (e.g. surgical excision, fine needle aspiration
biopsy, CNB) to acquire tissue samples for analysis. In some of the
latest studies, tCho peak (signal/concentration) obtained with
in vivo MR spectroscopy has shown good performances in
differentiating between malignant and benign breast lesions
[44,45], and also showed correlation with some histologic
prognostic factors [46–48]. In these studies, tCho was associated
with high histologic/nuclear grade, triple negative, ER-negative
cancers [46–48]. However, our results showed that tCho
concentrations of CNB samples were correlated only with cancers
strongly positive for Ki-67. This discrepancy may be resulted from
tumor heterogeneity. Our study and the previous studies above
mentioned included larger breast cancers. Heterogeneous charac-
ter of larger breast cancers may bring about variation in choline
metabolite concentrations of breast lesions. In the study by Bolan
et al., single-voxel MR spectroscopic data acquired from different
region of the same 3-cm breast cancer showed different tCho
concnentrations [49]. Therefore, single-voxel location of MR
spectroscopy and CNB specimen used for HR-MAS MR
spectroscopy may not represent the metabolic composition of
the large tumors. On the other hand, our study showed ER
negative, PR negative, and triple negative cancers, which were
found to be correlated with tCho in the previous studies using
in vivo MR spectroscopy, were correlated with Cho concentra-
tion. Cho is a contributor of tCho peak signal obtained with
in vivo MR spectroscopy and was found to be higher in tumors
larger than 2 cm in the previous study [16]. However, in vivo MR
spectroscopy cannot discriminate individual choline metabolites,
which contribute to the tCho signal, because it uses a relatively low
magnetic field strength (1.5–3.0 T) compared to HR-MAS MR
spectroscopy. Considering these and our results, the correlation
between tCho obtained with in vivo MR spectroscopy and the
prognostic factors (ER and PR status, triple negativity) may result
from higher Cho concentrations of the tumors. Therefore,
comparative study on choline markers of in vivo MR spectroscopy
and HR-MAS MR spectroscopy using CNB specimen may be
HR-MAS MR Spectroscopy of Breast Cancer Tissue
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needed to identify and verify correlation between them. And then,
if there is the correlation between in vivo MR spectroscopy and
HR-MAS MR spectroscopy using CNB specimen through the
comparison study, HR-MAS MR spectroscopy using breast tissue
obtained by minimally invasive CNB may prove to be a clinically
useful approach to provide metabolic information on tumors with
respect to invasiveness and data quality. Also, if in vivo MR
spectroscopy can use a high magnetic field strength (7.0 T) in the
future, the HR-MAS MR metabolic profile compiled with CNB
samples will be the foundation for future studies of high-field
results in vivo MR spectroscopy.
This study has several limitations. First, we excluded tumors
smaller than 1 cm in diameter and included a relatively small
number of tissue samples, which may have affected the results.
Second, we included breast cancers of variable size, and 12 tumors
(33.3%) were more than 3 cm in diameter. Larger breast cancers
are known to have heterogeneous histologic features, which may
induce variation in choline metabolite concentrations throughout
the breast lesion. However, we did not compare HR-MAS MR
spectroscopic values obtained with CNB specimens with the
spectroscopic values of whole tumors (e.g. HR-MAS MR
spectroscopic values obtained with surgical specimen, in vivo
multivoxel MR spectroscopic values of whole tumor). Therefore,
we cannot exclude the possibility that the CNB specimen used for
HR-MAS MR spectroscopy may not fully represent the metabolic
composition of the larger tumors. Finally, adjustments of
acquisition parameters are important in obtaining optimal spectral
data for HR-MAS MR spectroscopy. We tried to adjust the
acquisition parameters in each case when undertaking HR-MAS
MR spectroscopy in this study.
In conclusion, metabolic markers acquired with HR-MAS MR
spectroscopy using CNB specimens showed significant correlation
with histologic prognostic factors [ER, PR, HER2, triple
negativity, histologic grade, Ki-67, and poor prognosis (detection
of axillary lymph node metastasis, tumor size with a diameter
.2 cm, or negative for ER or PR)]. Our results indicate HR-MAS
MR spectroscopy using CNB specimens can be used to predict
tumor aggressiveness prior to surgery in patients with breast
cancer. In addition, it may be helpful for the detection of reliable
markers of breast cancer characterization.
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